18-Methoxycoronaridine acts in the medial habenula to attenuate behavioral and neurochemical sensitization to nicotine

Behavioural Brain Research

Volumn 307, Issue , 2016, Pages 186-193

  Eggan, Branden L ^a   McCallum, Sarah E ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

18 Methoxycoronaridine; Locomotor activity; Medial habenula; Microdialysis; Nicotine; Rat; Sensitization; 3 4 nicotinic acetylcholine receptors

Indexed keywords

18 METHOXYCORONARIDINE; ALPHA3BETA4 NICOTINIC ACETYLCHOLINE RECEPTOR; NICOTINE; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG; 18-METHOXYCORONARIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT; HOMOVANILLIC ACID; IBOGAINE; NICOTINIC AGENT;

ARTICLE; BEHAVIOR ASSESSMENT; BIOACCUMULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; HABENULA; HUMAN; LOCOMOTION; NEUROCHEMISTRY; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; SYSTEMIC THERAPY; TOBACCO DEPENDENCE; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; ANIMAL; BRAIN CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; FEMALE; METABOLISM; MICRODIALYSIS; RAT; SPRAGUE DAWLEY RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ANALYSIS OF VARIANCE; ANIMALS; BRAIN CHEMISTRY; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HABENULA; HOMOVANILLIC ACID; IBOGAINE; LOCOMOTION; MICRODIALYSIS; NICOTINE; NICOTINIC AGONISTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84962787684     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2016.04.008     Document Type: Article

References (41)

1. Antolin-Fontes B., Ables J.L., Gorlich A., Ibanez-Tallon I. The habenulo-interpeduncular pathway in nicotine aversion and withdrawal. Neuropharmacology 2015, 96:213-222.
2. Balfour D.J.K., Benwell M.E.M., Birrell C.E., Kelly J., Al-Aloul M. Senstization of the mesoaccumbens dopamine response to nicotine. Pharmacol. Biochem. Behav. 1998, 59:1021-1030.
3. Balfour D.J.K., Birrell C.E., Moran R.J., Benwell M.E.M. Effects of acute D-CPPene on mesoaccumbens dopamine responses to nicotine in the rat. Eur. J. Pharmacol. 1996, 316:153-156.
4. Brazell M.P., Mitchell S.N., Joseph M.H., Gray J.A. Acute administration of nicotine increases the in vivo extracellular levels of dopamine 3,4-dihydroxyphenylacetic acid and ascorbic acid preferentially in the nucleus accumbens of the rat: comparison with caudate-putamen. Neuropharmacology 1990, 29:1177-1185.
5. Benwell M.E., Balfour D.J. The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br. J. Pharmacol. 1992, 105:849-856.
6. Dluzen D.E., Anderson L.I. The effects of nicotine on dopamine and DOPAC output from rat striatal tissue. Eur. J. Pharmacol. 1998, 341:23-32.
7. Fowler C.D., Tuesta L., Kenny P.J. Role of α5* nicotinic acetylcholine receptors in the effects of acute and chronic nicotine treatment on brain reward function in mice. J. Psychopharmacol. 2011, 229:503-513.
8. Frahm S., Slimak M.A., Ferrarese L., Santos-Torres J., Antolin-f B., Auer S., Filkin S., Pons S., Fontaine J.F., Tsetlin V., Maskos U., Ibanes-Tallon I. Aversion to nicotine is regulated by the balanced activity of β4 and α5 nicotinic receptor subunits in the medial habenula. Neuron 2011, 70:522-535.
9. Frahm S., Antolin-Fontes B., Gorlich A., Zander J.F., Ahnert-Hilger G., Ibanez-Tallon I. An essential role of acetylcholine-glutamate synergy at habenular synapses in nicotine dependence. eLife 2015, 10:7554. Epub ahead of print.
10. Glick S.D., Kuehne M.E., Maisonneuve I.M., Bandarage U.K., Molinari H.H. 18-Methoxycoronaridine: a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and mesolimbic dopamine release in rats. Brain Res. 1996, 719:29-35.
11. Glick S.D., Maisonneuve I.M. Mechanisms of antiaddictive ibogaine. Ann. N. Y. Acad. Sci. 1998, 844:214-226.
12. Glick S.D., Maisonneuve I.M., Hough L.B., Keuhne M.E., Bandarage U.K. (±)-18-Methoxycoronaridine: a novel iboga alkaloid congener having potential anti-addictive efficacy. CNS Drug Rev. 1999, 1:27-42.
13. Glick S.D., Maisonneuve I.M., Dickinson H.A. 18-MC reduces methamphetamine and nicotine self-administration in rats. Neuroreport 2000, 11:2013-2015.
14. Glick S.D., Maisonneuve I.M., Szumlinski K.K. 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of anti-addictive efficacy, toxicity, and mechanism of action. Ann. N. Y. Acad. Sci. 2000, 914:369-386.
15. Glick S.D., Ramirez R.L., Livi J.M., Maisonneuve I.M. 18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats. Eur. J. Pharmacol. 2006, 537:94-98.
16. Glick S.D., Sell E.M., Maisonneuve I.M. Brain regions mediating α3β4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration. Eur. J. Pharmacol. 2008, 599:91-95.
17. Glick S.D., Sell E.M., McCallum S.E., Maisonneuve I.M. Brain regions mediating α3β4 nicotinic antagonist effects of 18-MC on nicotine self-administration. Eur. J. Pharmacol. 2011, 699:71-75.
18. Grady S.R., Moretti M., Zoli M., Marks M.J., Zanardi A., Pucci L., Clementi F., Gotti C. Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the α3β4* and α3β3β4* subtypes mediate acetylcholine release. J. Neurosci. 2009, 29:2272-2282.
19. Harrington L., Vinals X., Herrera-Solis, Flores A., Morel C., Tolu S., Faure P., Maldonado R., Maskos U., Robledo P. Role of β4* nicotinic acetylcholine receptors in the habenulo-interpeduncular pathway in nicotine reinforcement in mice. Neuropsychopharmacology 2015, 10.1038. Epub ahead of print.
20. Hung R.J., McKay J.D., Gaborieau V., et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008, 452:633-637.
21. Kalivas P.W., Sorg B.A., Hooks M.S. The pharmacology and neural circuitry of sensitization to psychostimulants. Behav. Pharmacol. 1993, 4:315-334.
22. Liu J.Z., Tozzi F., Waterworth D.M., et al. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat. Genet. 2010, 42:436-440.
23. McCallum S.E., Cowe M.A., Lewis S.W., Glick S.D. α3β4 nicotinic acetylcholine receptors in the medial habenula modulate the mesolimbic dopaminergic response to acute nicotine in vivo. Neuropharmacology 2012, 63:434-440.
24. Mulle C., Vidal C., Benoit P., Changeus J.P. Existence of different subtypes of nicotinic acetylcholine receptors in the rat habenulo-interpeduncular system. J. Neurosci. 1991, 11:2588-2597.
25. Nisell M., Nomikos G.G., Svensson T.H. Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 1994, 16(1991):36-44.
26. Pace C.J., Glick S.D., Maisonneuve I.M., He L.W., Jokiel P.A., Keuhne M.E., Fleck M.W. Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration. Eur. J. Pharmacol. 2004, 492:159-167.
27. Panagis G., Nisell M., Nomikos G.G., Chergui K., Svensson T.H. Nicotine injections into the ventral tegmental area increase locomotion and Fos-like immunoreactivity in the nucleus accumbens of the rat. Brain Res. 1996, 730:133-142.
28. Paxinos G., Watson C. The Rat Brain Stereotactic Coordinates 1986, Academic Press. second ed.
29. Quick M.W., Ceballos M.R., Kasten M., McIntosh M.J., Lester R.A. α3β4 subunit-containing nicotinic receptors dominate function in the medial habenula neurons. Neuropharmacology 1999, 38:769-783.
30. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. 1993, 18:247-291.
31. Saal D., Dong Y., Bonci A., Malenka R.C. Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons. Neuron 2003, 37:577-582.
32. Salas R., Pieri F., De Biasi M. Decreased signs of nicotine withdrawal in mice null for the β4 nicotinic acetylcholine receptor subunit. J. Neurosci. 2004, 24:10035-10039.
33. Salas R., Sturm R., Boulter J., De Biasi M. Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice. J. Neurosci. 2009, 29:3014-3018.
34. Schlaepfer I.R., Hoft N.R., Collins A.C., Corley R.P., Hewitt J.K., Hopfer C.J., Lessem J.M., McQueen M.B., Rhee S.H., Ehring M.A. The CHRNA5/A3/B4 gene cluster variability as an important determinant of early alcohol and tobacco initiation in young adults. Biol. Psychiatry 2008, 63:1039-1046.
35. Shoaib M., Benwell M.E.M., Akbar M.T., Stolerman I.P., Balfour D.J.K. Behavioural and neurochemical adaptation to nicotine in rats: influence of NMDA antagonists. Br. J. Pharmacol. 1994, 111:1073-1080.
36. Steketee J.D., Kalivas P.W. Drug wanting: behavioral sensitization and relapse to drug-seeking behavior. Pharmacol. Rev. 2011, 63:348-365.
37. Szumlinski K.K., Maisonneuve I.M., Glick S.D. The potential anti-addictive agent, 18-methoxycoronaridine, blocks the sensitized locomotor and dopamine responses produced by repeated morphine treatment. Bran Res. 2000, 864:13-23.
38. Szumlinski K.K., McCafferty C.A., Maisonneuve I.M., Glick S.D. Interactions between 18-methoxycoronaridine (18-MC) and cocaine: dissociation of behavioral and neurochemical sensitization. Brain Res. 2000, 21:245-248.
39. Toll L., Zaveri N.T., Polgar W.E., Jiang F., Khryoan T.V., Zhou W., Xie X., Stauber G.B., Costello M.R., Leslie F.M. AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats. Neuropsychopharmacology 2012, 37:1367-1376.
40. Zoli M., Moretti M., Zanardi A., McIntosh M.J., Clementi F., Gotti C. Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J. Neurosci. 2002, 22:8785-8789.
41. Zubaran C., Shoaib M., Stolerman I.P. The development and expression of locomotor sensitization to nicotine in the presence of ibogaine. Behav. Pharmacol. 2000, 11:431-436.